Preclinical Oncology Models for Testing Immunotherapies
4T1 is a triple-negative mouse breast cancer cell line. Pharmatest utilises a 4T1 cell line with stable expression of green fluorescent protein (GFP) enabling easy and efficient detection of whole-body tumour burden.
Condition: Breast Neoplasm Interventions: Drug: AZD6738; Drug: Olaparib; Drug: Durvalumab Sponsors: Institute of Cancer Research, United Kingdom; AstraZeneca Not yet recruiting
If approved, this Tecentriq combination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic triple-negative breast cancer
Conclusion: Within the overall goal to establish operating procedures for breast cancer immunotherapy, we propose to re-evaluate testing for deficient mismatch repair and to further intensify the search for biomarkers predictive for the success of immune checkpoint modulation including all tumor biologic subtypes of breast cancer.Breast Care
Roche's Tecentriq medicine will get a speedy review by U.S. regulators in a tough-to-treat form of breast cancer as the Swiss drugmaker seeks to be the first company to have its immunotherapy win approval in this indication.
By BISHAL GYAWALI MD Me-too deja vu I read the report of a phase 3 RCT of a “new” breast cancer drug but I had the feeling that I had already read this before. Later I realized that this was indeed a new trial of a new drug, but that I had read a very similar report of a very similar drug with very similar results and conclusions. This new drug is a PARP inhibitor called talazoparib and the deja vu was related to another PARP inhibitor drug called olaparib tested in the same patient population of advanced breast cancer patients with a BRCA mutation. The control arms were the same: physician ...
AbstractCancer vaccines have great potential in the fight against metastatic malignancies. Current anti-tumor immunotherapy is hindered by existing tolerance to tumor-associated antigens (TAA) and tumor escape using various mechanisms, highlighting the need for improved targets for immunotherapy. The cancer –testis antigen CTCFL/BORIS was discovered 16 years ago and possesses all features necessary for an ideal TAA. Recently CTCFL/BORIS has received additional attention as a target expressed in cancer stem cells (CSC). These cells drive tumor growth recurrence, metastasis, and treatment resistance. CTCFL/BORIS s...
CONCLUSION: IL-15 may improve the immunotherapeutic effects of NK-EVs, thus improving the applications of NK-EVs in the future. PMID: 30391801 [PubMed - as supplied by publisher]
Image credit: Houston Methodist Researchers at Houston Methodist Research Institute have created a nanodevice that can be used to deliver immunotherapy to treat triple-negative breast cancer. The tiny device is designed to be inserted directly into a tumor, delivering a localized, sustained-release dose of therapy and eliminating the need for patients to undergo IV treatments. Get the full story at our sister site, Drug Delivery Business News. The post Researchers develop nanodevice to deliver immunotherapy appeared first on MassDevice.
Conditions: TNBC - Triple-Negative Breast Cancer; Ovarian Cancer Interventions: Drug: AB928; Drug: Pegylated liposomal doxorubicin Sponsor: Arcus Biosciences, Inc. Recruiting